May 16, 2008 - Daiichi Sankyo, Inc. (DSI) announced today that data from two pooled analyses further demonstrate that Welchol™ (colesevelam HCl), in combination with metformin -- or sulfonylurea-based therapy, significantly lowers blood glucose (as measured by A1C) in patients with type 2 diabetes mellitus who had failed to achieve glycemic control (...). These findings, presented at the American Association of Clinical Endocrinologists' (AACE) 17th Annual Meeting and Clinical Congress, are the latest in a series of diabetes-related milestones for Welchol. In April, DSI announced that Welchol was added to the American College of Endocrinology (ACE)/AACE "Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus."... [PDF] Daiichi Sankyo's Press Release -
Tuesday, May 27, 2008
Daiichi Sankyo : Welchol, Combined With Metformin -- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults With Type 2 Diabetes
May 16, 2008 - Daiichi Sankyo, Inc. (DSI) announced today that data from two pooled analyses further demonstrate that Welchol™ (colesevelam HCl), in combination with metformin -- or sulfonylurea-based therapy, significantly lowers blood glucose (as measured by A1C) in patients with type 2 diabetes mellitus who had failed to achieve glycemic control (...). These findings, presented at the American Association of Clinical Endocrinologists' (AACE) 17th Annual Meeting and Clinical Congress, are the latest in a series of diabetes-related milestones for Welchol. In April, DSI announced that Welchol was added to the American College of Endocrinology (ACE)/AACE "Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus."... [PDF] Daiichi Sankyo's Press Release -
